A reformulation of existing approved drug typically requires only the demonstration of bioequivalence under the accelerated U.S. Food and Drug Administration (FDA) approval routes such as 505(b)2, and does not...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)